As of Aug 18
| +0.22 / +1.79%|
The 6 analysts offering 12-month price forecasts for Amicus Therapeutics Inc have a median target of 16.00, with a high estimate of 18.00 and a low estimate of 15.00. The median estimate represents a +27.90% increase from the last price of 12.51.
The current consensus among 6 polled investment analysts is to Buy stock in Amicus Therapeutics Inc. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.